Skip to main content
Premium Trial:

Request an Annual Quote

Agilent Labs, Stanford Pen Cardiovascular-Research Alliance

NEW YORK, Oct. 2 (GenomeWeb News) - Agilent Technologies and Stanford University will use Agilent's gene-expression technologies and computational expertise to analyze cardiovascular tissue samples from human patients, the groups said today.

 

Stanford's DonaldW.ReynoldsCardiovascularClinicalResearchCenterand Agilent Labs hope to use the technologies to identify, characterize, and validate diagnostic and drug targets that may help prevent, diagnose, and treat heart disease, according to a statement.

 

Financial terms of the agreement were not disclosed.

The Scan

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.

Circulating Tumor DNA Linked to Post-Treatment Relapse in Breast Cancer

Post-treatment detection of circulating tumor DNA may identify breast cancer patients who are more likely to relapse, a new JCO Precision Oncology study finds.

Genetics Influence Level of Depression Tied to Trauma Exposure, Study Finds

Researchers examine the interplay of trauma, genetics, and major depressive disorder in JAMA Psychiatry.

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.